Stocktoria
TALPHERA, INC. TLPH
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2011-02-11
TALPHERA, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28,000 | $0 | $651,000 | $0 | $2.8M | $5.4M | $2.3M | $2.2M | $8.0M | $17.4M |
| R&D expense | $6.0M | $6.7M | $5.5M | $3.3M | $4.1M | $4.0M | $4.7M | $13.1M | $19.4M | $21.4M |
| SG&A expense | $7.5M | $8.5M | $12.0M | $17.0M | $30.9M | $36.3M | $45.0M | $20.8M | $16.6M | — |
| Operating income | -$13.5M | -$15.3M | -$16.9M | -$25.3M | -$36.0M | -$41.0M | -$54.2M | -$35.7M | -$38.7M | -$32.0M |
| Interest expense | — | — | $134,000 | $1.1M | $2.3M | $3.3M | $2.5M | $2.2M | $3.3M | $2.8M |
| Income tax | $0 | $0 | $0 | $13,000 | $5,000 | $4,000 | $3,000 | $2,000 | -$701,000 | -$34,000 |
| Net income | -$14.3M | -$13.0M | -$18.4M | $47.8M | -$35.1M | -$40.4M | -$53.2M | -$47.1M | -$51.5M | -$43.2M |
| EPS (diluted) | — | — | $-1.29 | $5.72 | $-5.86 | — | — | — | $-1.10 | $-0.95 |
| Operating cash flow | -$11.4M | -$12.7M | -$17.5M | -$28.3M | -$30.0M | -$38.5M | -$51.2M | -$29.1M | -$29.8M | -$29.4M |
| Free cash flow | — | -$12.7M | -$17.6M | -$28.7M | -$31.8M | -$40.4M | -$54.6M | -$29.9M | -$32.2M | -$33.1M |
| Cash & equivalents | $5.9M | $8.9M | $5.7M | $15.3M | $7.7M | $22.3M | $14.7M | $88.0M | $52.9M | $80.3M |
| Inventory | — | — | — | $1.2M | $1.1M | $1.6M | $3.3M | $854,000 | $956,000 | $2.2M |
| Total assets | $29.7M | $18.2M | $20.4M | $47.5M | $77.9M | $66.3M | $91.4M | $120.5M | $75.6M | $100.0M |
| Total liabilities | $12.7M | $10.2M | $6.3M | $25.7M | $113.8M | $122.0M | $132.8M | $116.3M | $112.1M | $105.3M |
| Shareholders' equity | $17.0M | $8.0M | $14.1M | $21.8M | -$35.9M | -$55.8M | -$41.4M | $4.3M | -$36.5M | -$5.3M |
Growth · year-over-year · Revenue CAGR -51.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | — | -100.0% | -48.0% | +136.6% | +6.4% | -73.1% | -53.9% | -9.9% |
| Net income growth | — | — | -138.5% | — | — | — | — | — | — | — |
| EPS growth | — | — | -122.6% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.